Sensorion

Sensorion Total Assets

The Total Assets of Sensorion (ALSEN.PA) as of Oct 9, 2026 is 57.89 M EUR. In the previous year, Total Assets was 89.28 M EUR — a change of -35.16% (lower).

Total Assets

57.89 MEUR

YoY

-35.16%

Last updated:

Total Assets of Sensorion is 2025 57.89 M EUR. Total Assets of Sensorion was 2024 89.28 M EUR. It decreases by -35.16% lower compared to the previous year.

The Sensorion Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
9.47 M EUR
Jan 1, 2019
38.09 M EUR
Jan 1, 2020
67.87 M EUR
Jan 1, 2021
59.02 M EUR
Jan 1, 2022
38.93 M EUR
Jan 1, 2023
46.50 M EUR
Jan 1, 2024
89.28 M EUR
Jan 1, 2025
57.89 M EUR
The Sensorion Total Assets history
YEARTotal AssetsYoY
57.89 MEUR-35.16%
89.28 MEUR+91.98%
46.50 MEUR+19.45%
38.93 MEUR-34.03%
59.02 MEUR-13.05%
67.87 MEUR+78.17%
38.09 MEUR+302.37%
9.47 MEUR-15.18%
11.16 MEUR-5.83%
11.85 MEUR-28.26%
16.52 MEUR+653.59%
2.19 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sensorion stock

Total Assets of Sensorion is 57.89 M EUR in 2025.

Total Assets of Sensorion changed from 89.28 M EUR to 57.89 M EUR, representing a -35.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Sensorion since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Sensorion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Sensorion

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Sensorion